Obesity-related glomerulopathy: a lesser known complication of obesity.

IF 2.7 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2025-09-08 DOI:10.1097/MED.0000000000000930

Sourabh Sharma, Alok Sharma, Nitin Kapoor, Neha Sharma, Ponnusamy Saravanan, Sanjay Kalra

{"title":"Obesity-related glomerulopathy: a lesser known complication of obesity.","authors":"Sourabh Sharma, Alok Sharma, Nitin Kapoor, Neha Sharma, Ponnusamy Saravanan, Sanjay Kalra","doi":"10.1097/MED.0000000000000930","DOIUrl":null,"url":null,"abstract":"Purpose of review: Obesity is a global health concern and is intricately linked to cardiovascular disease and metabolic disorders. While its causal association with chronic kidney disease (CKD) has also been recognized, this entity has not been discussed extensively. Obesity-related glomerulopathy (ORG) is pathologically a secondary form of focal segmental glomerulosclerosis (FSGS), which typically presents clinically with subnephrotic proteinuria, and histopathologically as glomerulomegaly, and the perihilar variant of FSGS.Recent findings: This review discusses the latest update on pathophysiology, risk factors, clinical features, diagnosis, prevention, staging, and management of ORG. Special emphasis is placed on diagnostic criteria distinguishing ORG from other FSGS variants and CKD aetiologies.Summary: While obesity can impact renal health, renal status influences choice of antiobesity medication as well. Early recognition and intervention are critical to preventing progression to end-stage kidney disease.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Endocrinology & Diabetes and Obesity","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MED.0000000000000930","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Obesity is a global health concern and is intricately linked to cardiovascular disease and metabolic disorders. While its causal association with chronic kidney disease (CKD) has also been recognized, this entity has not been discussed extensively. Obesity-related glomerulopathy (ORG) is pathologically a secondary form of focal segmental glomerulosclerosis (FSGS), which typically presents clinically with subnephrotic proteinuria, and histopathologically as glomerulomegaly, and the perihilar variant of FSGS.

Recent findings: This review discusses the latest update on pathophysiology, risk factors, clinical features, diagnosis, prevention, staging, and management of ORG. Special emphasis is placed on diagnostic criteria distinguishing ORG from other FSGS variants and CKD aetiologies.

Summary: While obesity can impact renal health, renal status influences choice of antiobesity medication as well. Early recognition and intervention are critical to preventing progression to end-stage kidney disease.

查看原文本刊更多论文

肥胖相关性肾小球病变：一种鲜为人知的肥胖并发症。

综述目的：肥胖是一个全球性的健康问题，与心血管疾病和代谢紊乱有着复杂的联系。虽然其与慢性肾脏疾病（CKD）的因果关系也已得到承认，但这一实体尚未得到广泛讨论。肥胖相关性肾小球病（ORG）在病理上是局灶节段性肾小球硬化（FSGS）的一种继发性形式，临床上表现为亚肾病性蛋白尿，组织病理学上表现为肾小球肿大和FSGS的门周变异型。近期发现：本文综述了ORG的病理生理学、危险因素、临床特征、诊断、预防、分期和管理方面的最新进展。特别强调了区分ORG与其他FSGS变体和CKD病因的诊断标准。摘要：肥胖会影响肾脏健康，肾脏状况也会影响抗肥胖药物的选择。早期识别和干预是预防进展到终末期肾脏疾病的关键。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Endocrinology & Diabetes and Obesity ENDOCRINOLOGY & METABOLISM-

CiteScore

5.80

自引率

3.10%

发文量

128

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Endocrinology, Diabetes and Obesity delivers a broad-based perspective on the most recent and exciting developments in the field from across the world. Published bimonthly and featuring twelve key topics – including androgens, gastrointestinal hormones, diabetes and the endocrine pancreas, and neuroendocrinology – the journal’s renowned team of guest editors ensure a balanced, expert assessment of the recently published literature in each respective field with insightful editorials and on-the-mark invited reviews.